Abstract:Rett syndrome (RTT) is a progressive neurodevelopmental disorder that is caused by mutations in the X-linked methyl-CpG-binding protein2 (MECP2) gene. In this study, the MECP2 sequences in 121 unrelated Chinese patients with classical or atypical RTT were screened for deletions and mutations. In all, we identified 45 different MECP2 mutations in 102 of these RTT patients. The p. T158M mutation (15.7%) was the most common, followed in order of frequency by p. R168X (11.8%), p. R133C (6.9%), p. R270X (6.9%), p. … Show more
“…Indeed, the p.Ile72Thr mutation of patient 2 is the third affecting Ile72 to be discovered. A different change (p.Ile72Asn) was reported by Evans [21] and a silent change (p.Ile72Ile) was observed in a Chinese Rett cohort [4] and has so far been excluded as a polymorphism.…”
Section: Discussionmentioning
confidence: 58%
“…Following the description of two girls with West syndrome (OMIM#308350) carrying X;autosome translocations disrupting the cyclin-dependent kinase-like 5 gene (CDKL5; OMIM#300203) [1], other mutations within the same gene have been reported in patients manifesting a similar clinical picture, thus indicating that the associated phenotype is characterised by early-onset untreatable seizures, infantile spasms, severe mental retardation and some features of Rett syndrome (RTT: OMIM#312750) [2][3][4][5][6]. On the basis of this clinical presentation, the CDKL5-positive group has been assimilated to the Hanefeld early seizure variant of RTT [2].…”
It has been found that CDKL5 gene mutations are responsible for early-onset epilepsy and drug resistance. We screened a population of 92 patients with classic/ atypical Rett syndrome, 17 Angelman/Angelman-like patients and six idiopathic autistic patients for CDKL5 mutations and exon deletions and identified seven novel mutations: six in the Rett subset and one in an Angelman patient. This last, an insertion in exon 11, c.903_904 dupGA, p.Leu302Aspfx49X, is associated with a relatively mild clinical presentation as the patient is the only one capable of sitting and walking alone. Of the six mutations, two are de novo missense changes affecting highly conserved aminoacid residues, c.215 T>C p.Ile72Thr and c.380A>G p.His127Arg (present in a mosaic condition) found in two girls with the most severe clinical presentation, while the remaining are the splicing c.145+2 T>C and c.2376 + 5G > A, the c.1648C > T p.Arg550X and the MPLA-identified c.162_99del261 mutation. RNA characterisation of four mutations revealed the aberrant transcript of the missense allele (case 2) and not the stop mutation (case 3), but also allowed the splicing mutation (case 1) and the c.-162_99del261 (case 4) to be categorised as truncating. The obtained data reinforce the view that a more severe phenotype is due more to an altered protein than haploinsufficiency. Furthermore, the mutational repertoire of the CDKL5 gene is shown to be expanded by testing patients with phenotypical overlap to Rett syndrome and applying multiplex ligation-dependent probe amplification.
“…Indeed, the p.Ile72Thr mutation of patient 2 is the third affecting Ile72 to be discovered. A different change (p.Ile72Asn) was reported by Evans [21] and a silent change (p.Ile72Ile) was observed in a Chinese Rett cohort [4] and has so far been excluded as a polymorphism.…”
Section: Discussionmentioning
confidence: 58%
“…Following the description of two girls with West syndrome (OMIM#308350) carrying X;autosome translocations disrupting the cyclin-dependent kinase-like 5 gene (CDKL5; OMIM#300203) [1], other mutations within the same gene have been reported in patients manifesting a similar clinical picture, thus indicating that the associated phenotype is characterised by early-onset untreatable seizures, infantile spasms, severe mental retardation and some features of Rett syndrome (RTT: OMIM#312750) [2][3][4][5][6]. On the basis of this clinical presentation, the CDKL5-positive group has been assimilated to the Hanefeld early seizure variant of RTT [2].…”
It has been found that CDKL5 gene mutations are responsible for early-onset epilepsy and drug resistance. We screened a population of 92 patients with classic/ atypical Rett syndrome, 17 Angelman/Angelman-like patients and six idiopathic autistic patients for CDKL5 mutations and exon deletions and identified seven novel mutations: six in the Rett subset and one in an Angelman patient. This last, an insertion in exon 11, c.903_904 dupGA, p.Leu302Aspfx49X, is associated with a relatively mild clinical presentation as the patient is the only one capable of sitting and walking alone. Of the six mutations, two are de novo missense changes affecting highly conserved aminoacid residues, c.215 T>C p.Ile72Thr and c.380A>G p.His127Arg (present in a mosaic condition) found in two girls with the most severe clinical presentation, while the remaining are the splicing c.145+2 T>C and c.2376 + 5G > A, the c.1648C > T p.Arg550X and the MPLA-identified c.162_99del261 mutation. RNA characterisation of four mutations revealed the aberrant transcript of the missense allele (case 2) and not the stop mutation (case 3), but also allowed the splicing mutation (case 1) and the c.-162_99del261 (case 4) to be categorised as truncating. The obtained data reinforce the view that a more severe phenotype is due more to an altered protein than haploinsufficiency. Furthermore, the mutational repertoire of the CDKL5 gene is shown to be expanded by testing patients with phenotypical overlap to Rett syndrome and applying multiplex ligation-dependent probe amplification.
“…The second alteration, Ala370Thr, was identified in a singleton family of African ancestry and previously reported in three Chinese individuals: one female with Rett syndrome, her unaffected mother and a male presenting with epileptic encephalopathy [Fig. C; Li, Pan, Bao, Zhang, & Wu, ; Wong & Li, ]. Both of these alterations must be further evaluated to isolate their potential functional consequences.…”
The methyl-CpG-binding domain (MBD) gene family was first linked to autism over a decade ago when Rett syndrome, which falls under the umbrella of autism spectrum disorders (ASDs), was revealed to be predominantly caused by MECP2 mutations. Since that time, MECP2 alterations have been recognized in idiopathic ASD patients by us and others. Individuals with deletions across the MBD5 gene also present with ASDs, impaired speech, intellectual difficulties, repetitive behaviors, and epilepsy. These findings suggest that further investigations of the MBD gene family may reveal additional associations related to autism. We now describe the first study evaluating individuals with ASD for rare variants in four autosomal MBD family members, MBD5, MBD6, SETDB1, and SETDB2, and expand our initial screening in the MECP2 gene. Each gene was sequenced over all coding exons and evaluated for copy number variations in 287 patients with ASD and an equal number of ethnically matched control individuals. We identified 186 alterations through sequencing, approximately half of which were novel (96 variants, 51.6%). We identified seventeen ASD specific, nonsynonymous variants, four of which were concordant in multiplex families: MBD5 Tyr1269Cys, MBD6 Arg883Trp, MECP2 Thr240Ser, and SETDB1 Pro1067del. Furthermore, a complex duplication spanning the MECP2 gene was identified in two brothers who presented with developmental delay and intellectual disability. From our studies, we provide the first examples of autistic patients carrying potentially detrimental alterations in MBD6 and SETDB1, thereby demonstrating that the MBD gene family potentially plays a significant role in rare and private genetic causes of autism.
“…Besides the classical form, several variant forms such as mental retardation with spasticity, congenital hypotonia with infantile spasms or severe neonatal encephalopathy in males have been delineated. Although in about 90% of patients with classical Rett syndrome mutations or deletions of the X-linked MECP2 gene were detectable, less than 50% of atypical patients showed MECP2 defects [Fukuda et al, 2005;Kammoun et al, 2004;Li et al, 2007;Zahorakova et al, 2007]. Few of the MECP2 negative patients were recently shown to suffer from CDKL5 [Archer et al, 2006;Weaving et al, 2004] or FOXG1 [Ariani et al, 2008;Mencarelli et al, 2010;Philippe et al, 2010] mutations.…”
The etiology of mental retardation remains elusive in the majority of cases. Microdeletions within chromosomal bands 5q14.3q15 were recently identified as a recurrent cause of severe mental retardation, epilepsy, muscular hypotonia, and variable minor anomalies. By molecular karyotyping we identified two novel 2.4- and 1.5-Mb microdeletions of this region in patients with a similar phenotype. Both deletions contained the MEF2C gene, which is located proximally to the previously defined smallest region of overlap. Nevertheless, due to its known role in neurogenesis, we considered MEF2C as a phenocritical candidate gene for the 5q14.3q15 microdeletion phenotype. We therefore performed mutational analysis in 362 patients with severe mental retardation and found two truncating and two missense de novo mutations in MEF2C, establishing defects in this transcription factor as a novel relatively frequent autosomal dominant cause of severe mental retardation accounting for as much as 1.1% of patients. In these patients we found diminished MECP2 and CDKL5 expression in vivo, and transcriptional reporter assays indicated that MEF2C mutations diminish synergistic transactivation of E-box promoters including that of MECP2 and CDKL5. We therefore conclude that the phenotypic overlap of patients with MEF2C mutations and atypical Rett syndrome is due to the involvement of a common pathway.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.